extended-spectrum beta-lactamases (ESBLs)
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:enzyme
antibiotic resistance mechanism |
| gptkbp:detects |
antibiotic susceptibility testing
molecular methods |
| gptkbp:firstDescribed |
1980s
|
| gptkbp:function |
hydrolyze beta-lactam antibiotics
|
| https://www.w3.org/2000/01/rdf-schema#label |
extended-spectrum beta-lactamases (ESBLs)
|
| gptkbp:inhibitedBy |
gptkb:clavulanic_acid
gptkb:sulbactam tazobactam |
| gptkbp:notEffectiveAgainst |
carbapenems
|
| gptkbp:producedBy |
gptkb:Proteus_mirabilis
gptkb:Pseudomonas_aeruginosa gptkb:Enterobacter_cloacae gptkb:Bacteria gptkb:Klebsiella_pneumoniae |
| gptkbp:proteinFamily |
gptkb:blaTEM
blaCTX-M blaSHV |
| gptkbp:publicHealthConcern |
antibiotic resistance crisis
|
| gptkbp:resistantTo |
gptkb:cephalosporins
gptkb:aztreonam penicillins |
| gptkbp:significance |
cause community-acquired infections
cause hospital-acquired infections |
| gptkbp:treatmentOption |
carbapenems
beta-lactamase inhibitor combinations |
| gptkbp:bfsParent |
gptkb:SHV-1
|
| gptkbp:bfsLayer |
8
|